The immuno-oncology treatment developer secured series B funding from investors including Legend Capital, a year after its $50m series A round.

China-based immuno-oncology treatment developer MediLink Therapeutics has raised $70m in series B funding from investors including Legend Capital, the venture capital firm formed by conglomerate Legend Holding, DealStreetAsia reported on Monday.

Lyfe Capital and Qiming Venture Partners co-led the round, which also featured Loyal Valley Capital and HighLight Capital.

Founded in 2020, MediLink is developing antibody-drug conjugates (ADCs) to treat cancer. It is looking to begin clinical trials for its most advanced drug candidates later this year in the United…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn